Fumito Ito, MD, PhD is Associate Professor of Oncology, Department of Surgical Oncology, Member, Center for Immunotherapy, Roswell Park Cancer Institute; Associate Professor of Surgery, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo. He is a co-author of Immune Checkpoint Inhibitors in Cancer.
After earning his medical degree from the Shiga University, Japan, Dr. Ito completed his postgraduate training in Surgery at the Shiga University Hospital. He then performed a research fellowship in Tumor Immunology at the University of Michigan and earned his PhD from the Shiga University. He completed his surgery residency training at the University of Wisconsin and Surgical Oncology fellowship training at the Roswell Park Comprehensive Cancer Center.
Dr. Ito has a significant clinical interest in melanoma, sarcoma, breast, and gastrointestinal cancer. His research interests include the development of novel cancer immunotherapy using pluripotent stem cells, and the use of genome-engineering technology to augment anti-cancer responses, and elucidate the immunomodulatory mechanisms of ablative techniques such as radiofrequency and cryoablation.
Dr. Ito is a member of the American College of Surgeons, the Society of Surgical Oncology, the Central Surgical Association, the American Association for Cancer Research, the American Association of Immunologists, and the Society of Thermal Medicine. He has won numerous awards and honors, including STL Cure Sarcoma Research Award, Trainee Abstract Award from the American Association of Immunologists, Young Investigator Award from Melanoma Research Alliance, Turcotte Enrichment Award from Central Surgical Association Foundation, American College of Surgeons Faculty Research Fellowship Award, and more.
Leave A Comment